Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Osmotin is a plant-derived protein belonging to the pathogenesis-related (PR)-5 family, originally isolated from *Nicotiana tabacum*. It is a structural and functional homolog of the mammalian hormone adiponectin. Korea Pharma is developing Osmotin as a neuroprotective agent for the treatment of dementia, specifically Alzheimer's disease. The protein acts as an adiponectin receptor 1 (AdipoR1) agonist. By activating AdipoR1, it triggers downstream signaling pathways, such as the AMPK/SIRT1 axis, which reduce neuroinflammation, inhibit the accumulation of amyloid-beta (Aβ) plaques, and prevent tau protein hyperphosphorylation. These actions collectively aim to mitigate neurodegeneration and cognitive decline associated with Alzheimer's disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Osmotin.